ArticleScientific reports2026
Aluminum adjuvants differentially induce IL-1β release in vitro yet share NLRP3 inflammasome-independent adjuvant effects in vivo.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanisms and therapeutic prospects of DNA methylation-mucosal innate immunity crosstalk in inflammatory bowel disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Aluminum adjuvants are the most common adjuvants in human vaccines. The two types of aluminum adjuvants, aluminum hydroxide adjuvant (AH) and aluminum phosphate adjuvant (AP), differ in physical and chemical characteristics, but little is known about possible biological differences. While previous work demonstrated that AH and AP induce the secretion of IL-1β in an NLRP3-dependent manner, the role of NLRP3 in the stimulation of the immune response by aluminum adjuvants is controversial. Here, we report that AP induces more IL-1β in human and mouse macrophages and dendritic cells than AH. This effect is caused by increased NLRP3-dependent proteolysis of pro-IL-1β. In addition, AP caused a greater degree of cell damage than AH, resulting in the release of lactate dehydrogenase (LDH) and pro-IL-1β. The cell damage caused by aluminum adjuvants was partially dependent on NLRP3, suggesting that pyroptosis and other mechanisms of cell death are involved. In spite of these differences in NLRP3-dependent production of IL-1β, the ability of both aluminum adjuvants to enhance the antibody response in two different mouse models was not affected by deletion or inhibition of NLRP3. These results support the concept that aluminum adjuvants elicit redundant innate immune mechanisms that result in an enhanced adaptive immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.